Research programme: alpha-7 nicotinic acetylcholine receptor agonists - Pfizer

Drug Profile

Research programme: alpha-7 nicotinic acetylcholine receptor agonists - Pfizer

Alternative Names: CP-810,123; PHA 785454; PHA-543613E; PHA-568487; PHA-758454; PNU-120596; PNU-282987

Latest Information Update: 05 Aug 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Schizophrenia

Most Recent Events

  • 05 Aug 2009 This programme is in active development
  • 21 Aug 2008 PHA 758454 identified as a lead candidate
  • 07 Nov 2007 Pharmacodynamics data from a preclinical trial in Schizoprenia presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top